GLP-1 receptor agonists are revolutionizing obesity treatment by achieving significant and sustainable weight loss through their effects on the central nervous system, as discussed by Professor Stavroula Paschou.

Pharmaceutical companies Lilly and Novo Nordisk saw their stock prices increase following a proposal from the FDA to exclude GLP-1 receptor agonists from the compounding list.

New research suggests that GLP-1 receptor agonists, drugs typically used for type 2 diabetes and obesity, may possess anti-inflammatory properties beneficial for patients with dermatological diseases. This finding comes from a summary of current knowledge on their application in dermatology.

GLP-1 receptor agonists and newer GIP/GLP-1 dual agonists have significantly changed obesity treatment, offering substantial and sustainable weight loss, with experts discussing their use during pregnancy.